NCT02818348View on ClinicalTrials.gov

Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

October 31, 2016

Study Completion Date

November 23, 2016

Conditions
HIV-1 Infection
Interventions
DRUG

darunavir/cobicistat

800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days

DRUG

etravirine

400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days

Trial Locations (1)

08916

Fundació Lluita contra la SIDA, Badalona

All Listed Sponsors
lead

Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia

OTHER

NCT02818348 - Clinical Trial to Evaluate Drug-drug Interactions Between Darunavir/Cobicistat and Etravirine in Hiv- Infected Patients | Biotech Hunter | Biotech Hunter